Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 40 mg/day showed no clear difference in serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.1 [0.94, 1.2]
1 study · 1324 participants
Moderate

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 80 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (low certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 1.8 [1.6, 2.2]
3 studies · 2193 participants
Low

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
RR 2.2 [1.9, 2.5]
2 studies · 880 participants
Moderate